{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:06:56Z","timestamp":1764173216418,"version":"3.46.0"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Standardized pharmacist intervention practices and documentation among health-system specialty pharmacies could improve understanding of the pharmacists\u2019 role and value in this setting. This study describes current health-system specialty pharmacies\u2019 intervention practices. A survey developed by a volunteer committee subgroup was distributed to two health-system specialty pharmacy group email distribution lists. The survey evaluated the types of tasks considered to be clinical or non-clinical interventions; who could perform interventions; where and how they were documented; data elements included in documentation; and how intervention data were classified, used, reviewed, and shared with internal or external stakeholders. Twenty-four institutions responded to the survey. Tasks within medication management, adverse drug events\/monitoring, and education domains were more commonly considered clinical interventions; tasks in the health maintenance and coordination of care domains were more frequently considered non-clinical interventions or not considered to be interventions. Interventions were completed by pharmacists (at 100% of sites) and were mostly documented in the electronic health record (92%). Intervention data were primarily collected to meet accreditation purposes (96%) or for quality auditing and review (88%). No respondents shared intervention data with patients. Results demonstrate areas of alignment and variance in intervention definition and documentation among health-system specialty pharmacies.<\/jats:p>","DOI":"10.3390\/pharmacy13060172","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:56:41Z","timestamp":1764172601000},"page":"172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Capturing Value: How Health-System Specialty Pharmacies Define and Document Pharmacist Interventions"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-0691","authenticated-orcid":false,"given":"Autumn D.","family":"Zuckerman","sequence":"first","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt Health, Nashville, TN 37211, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-7409","authenticated-orcid":false,"given":"Karen C.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Diamantides","sequence":"additional","affiliation":[{"name":"Tufts Medicine Pharmacy, Tufts Medicine, Boston, MA 02111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-5547","authenticated-orcid":false,"given":"Shannan","family":"Takhar","sequence":"additional","affiliation":[{"name":"University of California San Francisco School of Pharmacy, University of California Davis Health, San Francisco, CA 94143, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushabh","family":"Shah","sequence":"additional","affiliation":[{"name":"University of North Carolina Health Specialty and Home Delivery Pharmacy, University of North Carolina Health, Morrisville, NC 27560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-7455","authenticated-orcid":false,"given":"Kelsi","family":"Conant","sequence":"additional","affiliation":[{"name":"West Virginia University Medicine Specialty Pharmacy, West Virginia University Medicine, Morgantown, WV 26505, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thom","family":"Platt","sequence":"additional","affiliation":[{"name":"University of Kentucky HealthCare Specialty Pharmacy and Infusion Services, University of Kentucky HealthCare, Lexington, KY 40536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rhudy","sequence":"additional","affiliation":[{"name":"University of Kentucky HealthCare Specialty Pharmacy and Infusion Services, University of Kentucky HealthCare, Lexington, KY 40536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2146\/ajhp070506","article-title":"Economic effects of clinical pharmacy interventions: A literature review","volume":"65","author":"Willems","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/archinte.166.9.955","article-title":"Clinical pharmacists and inpatient medical care: A systematic review","volume":"166","author":"Kaboli","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4212\/cjhp.v66i4.1267","article-title":"Assessment of clinical pharmacy interventions in the intensive care unit","volume":"66","author":"Ho","year":"2013","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ajhp\/59.16.1518","article-title":"Impact of a collaborative pharmacy practice model on the treatment of depression in primary care","volume":"59","author":"Finley","year":"2002","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2125.1999.00964.x","article-title":"Clinical pharmacy interventions by community pharmacists during the dispensing process","volume":"47","author":"Hawksworth","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","first-page":"379","article-title":"Effect of clinical pharmacist interventions on cost in an integrated health system specialty pharmacy","volume":"27","author":"Lankford","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.japh.2020.11.009","article-title":"Economic impact of pharmacist interventions in pediatric ambulatory care clinics","volume":"61","author":"Yung","year":"2021","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_8","first-page":"336","article-title":"Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis","volume":"30","author":"Georgieva","year":"2024","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/ajhp\/zxab211","article-title":"Proposed guidance on cost-avoidance studies in pharmacy practice","volume":"78","author":"Patanwala","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/ajhp\/zxab277","article-title":"ASHP National Survey of Health-System Specialty Pharmacy Practice\u20142020","volume":"78","author":"Stubbings","year":"2021","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ajhp\/zxad064","article-title":"2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services","volume":"80","author":"Zuckerman","year":"2023","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/ajhp\/zxac212","article-title":"Health-system specialty pharmacy role and outcomes: A review of current literature","volume":"79","author":"Zuckerman","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/ajhp\/zxad235","article-title":"ASHP Survey of Health-System Specialty Pharmacy Practice: Practice Models, Operations, and Workforce-2022","volume":"80","author":"Kelley","year":"2023","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_14","unstructured":"Bonome, H., and Donovan, J. (2023). Pharmacy Hot Take: Tracking Your Clinical Intervention Outcomes, URAC. Available online: https:\/\/www.urac.org\/wp-content\/uploads\/2023\/06\/Tracking-Clinical-Interventions-Webinar-Slides.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1093\/ajhp\/zxab257","article-title":"A pharmacist-managed virtual consult service to improve tuberculosis screening","volume":"79","author":"Sasnovskaya","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_16","first-page":"765","article-title":"Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center","volume":"25","author":"Farano","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ygyno.2020.12.039","article-title":"The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?","volume":"160","author":"Goldsberry","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Shah, N.B., Mitchell, R.E., Proctor, S.T., Choi, L., DeClercq, J., Jolly, J.A., Hemnes, A.R., and Zuckerman, A.D. (2019). High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217798"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ppul.24446","article-title":"Impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center","volume":"54","author":"Wright","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_20","first-page":"407","article-title":"The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients","volume":"23","author":"Zullig","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_21","first-page":"989","article-title":"Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation","volume":"28","author":"Roder","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.anai.2024.07.012","article-title":"Role of an embedded health system specialty pharmacy on prescription of biologics in allergy\/immunology","volume":"133","author":"Patrawala","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_23","first-page":"198","article-title":"Assessing the impact of limited distribution drug networks on time to access oral oncolytic agents at an integrated specialty pharmacy","volume":"10","author":"Wyatt","year":"2020","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"ref_24","first-page":"815","article-title":"Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System","volume":"23","author":"Bagwell","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jacl.2019.01.003","article-title":"Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates","volume":"13","author":"Reynolds","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/21556660.2019.1658304","article-title":"Impact of specialty pharmacy taking ownership of the prior authorization process of multiple sclerosis specialty medications to increase access to infusible disease-modifying therapy (DMT)","volume":"8","author":"Whetstone","year":"2019","journal-title":"J. Drug Assess."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1002\/ppul.25554","article-title":"Impact of a Pharmacy Technician and Pharmacist on Time to Inhaled Tobramycin Therapy in a Pediatric Cystic Fibrosis Clinic","volume":"56","author":"Burrus","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/ibd\/izad012","article-title":"Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease","volume":"29","author":"Choi","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"otad018","DOI":"10.1093\/crocol\/otad018","article-title":"Role and Impact of a Clinical Pharmacy Team at an Inflammatory Bowel Disease Center","volume":"5","author":"Choi","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zuckerman, A.D., Carver, A., Cooper, K., Markley, B., Mitchell, A., Reynolds, V.W., Saknini, M., Wyatt, H., and Kelley, T. (2019). An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities. Pharmacy, 7.","DOI":"10.3390\/pharmacy7040163"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102262","DOI":"10.1016\/j.japh.2024.102262","article-title":"Implementing a Letter Template to Expedite Specialty Medication Appeal Letter Submission","volume":"65","author":"Fann","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dale, J.R., Murray, R.L., Levet, C.M., and Babin, S.F. (2025). Beyond the call: Implementing a patient-first digital refill solution in a health-system specialty pharmacy. Am. J. Health Syst. Pharm., zxaf192.","DOI":"10.1093\/ajhp\/zxaf192"},{"key":"ref_33","unstructured":"Starr, M. (2025). Specialty Pharmacy Interventions Framework. NASP\u2019s 5-Step Procedure Tracks Patient Intervention Effectiveness, Specialty Pharmacy Continuum. Available online: https:\/\/www.specialtypharmacycontinuum.com\/Clinical\/Article\/02-25\/Specialty-Pharmacy-Interventions-Framework\/76219?ses=ogst."},{"key":"ref_34","unstructured":"Pharmacy Quality Alliance (2025). Medication Management Services, Pharmacy Quality Alliance. Available online: https:\/\/www.pqaalliance.org\/medication-management-services."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:03:35Z","timestamp":1764173015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmacy13060172"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13060172","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}